Search Results for: Clinical Roundup
-
Derma Sciences Enters Home Stretch with $29.3M Funding
RedHill Biopharma Ltd., of Tel Aviv, Israel, said it completed a private placement of approximately $6.5 million, which will be used to advance the company's late clinical-stage programs...It also plans to start a Phase IIa trial with RHB-104 for the treatment of multiple sclerosis in January 2013.By Catherine Shaffer | BioWorld Today | Friday, December 7, 2012 -
Clinic Roundup
BCI-838 showed a favorable safety profile, with no treatment-related trends in clinical laboratory results, vital sign measurements, 12 lead ECG results or physical examination findings, and the drug was well tolerated up to the dose levels predicted for efficacyBioWorld Today | Thursday, December 6, 2012 -
Clinic Roundup
NeuroVive Pharmaceutical AB, of Lund, Sweden, said Phase I data published in Clinical Drug Investigation showed that its CicloMulsion, a Cremophor-free intravenous cyclosporine formula, was bioequivalent to Sandimmune injection and was safe and well tolerated...CicloMulsion is a cyclophilin inhibitor in clinical development to treat cardiac reperfusion injury and, under the name NeuroSTAT, in development for traumatic brain injuryBioWorld Today | Wednesday, December 5, 2012 -
Zafgen $21M Raise to Move Beloranib Beyond Phase IIa
The Series D enables Zafgen to move clinical and regulatory activities forward without the distraction of additional fundraising, Hurwitz added...Proceeds will support a Phase III trial of Multikine (leukocyte interleukin, injection).By Marie Powers | BioWorld Today | Wednesday, December 5, 2012 -
Pharma: Clinic Roundup
Because of the nature of the registry and vision testing variability, the company said, a clear comparison could not be drawn between registry data and clinical trial resultsBioWorld Today | Tuesday, December 4, 2012 -
Financings Roundup
Net proceeds are expected to total about $44.7 million – or $51.5 million if underwriters exercise in full their overallotment option for 900,000 additional shares – and will be used for commercial launch activities and continued clinical development of the firm's pipeline of extended-release drugsBioWorld Today | Monday, December 3, 2012 -
CBO: New Findings on Prescriptions, Medicare Spend
FDA Seeks Comments on Cellular, Gene Therapy The FDA made available a draft document relating to preclinical assessment of cellular and gene therapy products providing guidance on the substance and scope of information needed to support clinical trials...The brief was filed in connection with an antitrust action against Warner Chilcott, alleging that Warner Chilcott maintained a monopoly for its antibacterial drug Doryx by reformulating the drug three times.By Staff Reports | BioWorld Today | Monday, December 3, 2012 -
Rib-X Skips IPO, Opts for $67.5M Equity Financing
delafloxacin showed an 88 percent clinical response rate dosed at 300 mg twice daily, compared to 82 percent for Tygacil (tigecyline, Pfizer Inc...A separate Phase II trial in community-acquired pneumonia showed an 87 percent clinical response rate at 200-mg and 400-mg doses of oral delafloxacin...Shares of Rexahn (NYSE:RNN) fell 14 cents, or 30.3 percent, to close Thursday at 33 cents.By Catherine Shaffer | BioWorld Today | Friday, November 30, 2012 -
Clinic Roundup
Top-line data from the PEARL-SC trial, presented in June, showed the drug missed its primary endpoint, defined as clinical improvement at 24 weeks in the SLE responder index, but further data showed that the BAFF inhibitor produced sustained and greater treatment effects vsBioWorld Today | Thursday, November 29, 2012 -
Clinic Roundup
Accera Inc., of Broomfield, Colo., started a clinical efficacy trial examining the effects of AC-1204 in patients with mild-to-moderate Alzheimer's disease (ADBioWorld Today | Tuesday, November 27, 2012 -
TxCell Lands $16M to Advance Immunotherapy for Crohn's
regulators are happy to see a clinical response, whereas European regulators seek the more stringent outcome of remission...Proceeds will be used to advance the clinical development of EPI-743...The drug previously demonstrated efficacy in prostate, breast and ovarian cancer models, as well as in endometriosis, and the recent fundraising is expected to move VAL201 through first-in-human clinical trials.By Cormac Sheridan | BioWorld Today | Tuesday, November 27, 2012 -
Clinic Roundup
Subcutaneous administration achieved efficient conversion to decitabine, resulting in an improved pharmacokinetic profile over the intravenous Dacogen (decitabine) formulation, and clinical responses were observed in the heavily pretreated population of patients with relapsed/refractory intermediate- or high-risk myelodysplastic syndromes or acute myelogenous leukemiaBioWorld Today | Wednesday, November 21, 2012 -
FDA Issues Final Guidance on Drug Manufacturing Processes
Using Electronic Data in Clinical Trials The FDA also is requesting comments on a revised draft guidance on the use of electronic source data in clinical trials...The document is designed to help sponsors, contract research organizations, data management centers, clinical investigators and others involved in capturing, reviewing and archiving electronic source data in FDA-regulated clinical trials to ensure the reliability, quality, integrity and traceability of the dataBy Staff Reports | BioWorld Today | Tuesday, November 20, 2012 -
Washington Roundup
The Patient-Centered Outcomes Research Institute (PCORI) will award $12 million in funding through 14 contracts for studies addressing knowledge gaps in comparative clinical effectiveness researchBioWorld Today | Monday, November 19, 2012 -
Clinic Roundup
Trial data showed clinical benefit, defined as partial response and stable disease of more than four months following up to eight cycles of treatment, at the maximum tolerated dose in 10 of 13 evaluable patientsBioWorld Today | Friday, November 16, 2012 -
Pharma: Clinic Roundup
Bayer Inc., of Deerfield, Ill., and the Population Health Research Institute said they started the COMPASS trial, the largest clinical study to date of oral anticoagulant rivaroxabanBioWorld Today | Wednesday, November 14, 2012 -
ACR-ARHP Roundup
The data, compared to month three, showed a further improvement in clinical symptoms linked to RA for patients in whom the Kinoid induced antibody (Abs) to TNF, compared to those without such antibodyBioWorld Today | Tuesday, November 13, 2012 -
Clinic Roundup
The primary endpoint of the study is clinical benefit of AEZS-108...The study, conducted in 20 Asian patients at seven clinical trial sites, compared the outcome of a single intravenous dose of Zybrestat (15, 25, 35 or 45 mg/kg) with placebo...Based on outcomes for safety and tolerability, and measures of absorption, distribution, metabolism and excretion, Path will proceed to the next Phase of clinical trials in 2013BioWorld Today | Tuesday, November 13, 2012 -
Pharma: Clinic Roundup
The data were presented during a late-breaking clinical trials session at the 9th International Congress of the Society for Melanoma Research in Hollywood, CalifBioWorld Today | Tuesday, November 13, 2012 -
Pharma: Clinic Roundup
The Phase III study met its primary endpoint and demonstrated statistically significant protection against clinical and severe malaria in infants...In the trial, infants (ages 6-12 weeks at first vaccination) receiving the RTS,S vaccine candidate experienced one-third fewer episodes of both clinical and severe malaria and experienced similar reactions to the injection when compared to those who received the control meningococcal C conjugate vaccineBioWorld Today | Monday, November 12, 2012
Category
Current Filters
- xNOT drug application
Related Keywords
Categories
- x BioWorld Today (1799)
- x BioWorld International (49)
- x Bio Perspectives (4)
- x BioWorld Insight (2)
- x State of the Industry Report (2)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.